General Information of Drug (ID: DMVX8LO)

Drug Name
AZ11657312 (salt free) Drug Info
Synonyms AZ11657312 (salt free); SCHEMBL5079735; GTPL7722; CHEMBL550637
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11193842
TTD Drug ID
DMVX8LO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting P2X purinoceptor 7 (P2RX7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CE-224535 DMFCLT6 Arthralgia ME82 Phase 2/3 [3]
AZD9056 DMJGYPK Chronic obstructive pulmonary disease CA22 Phase 2 [4]
LY3857210 DMZO2V2 Pain MG30-MG3Z Phase 2 [5]
BIL010t DMV1EA9 Alzheimer disease 8A20 Phase 1/2 [6]
EVT 401 DMOG8IE Rheumatoid arthritis FA20 Phase 1 [7]
SGM-1019 DMDAHEL Inflammatory bowel disease DD72 Phase 1 [8]
GSK1482160 DMWDQOV Pain MG30-MG3Z Phase 1 [9]
JNJ-55308942 DM0QZJX Anhedonia MB24.2 Phase 1 [6]
JNJ-54175446 DMQ5ZVK Major depressive disorder 6A70.3 Phase 1 [10]
JNJ-479655 DMDU6GN Alzheimer disease 8A20 Clinical trial [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2X purinoceptor 7 (P2RX7) TT473XN P2RX7_HUMAN Antagonist [2]

References

1 The role of the purinergic P2X7 receptor in inflammation. J Inflamm (Lond). 2007 Mar 16;4:5.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484).
3 Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
4 Clinical pipeline report, company report or official report of AstraZeneca (2009).
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
6 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
7 Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40.